More than half had never used a GLP-1 drug before, suggesting the pill is bringing in new patients rather than just switchers, researchers say.
Recap by typeshit. Full story at Physicians Weekly.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Lilly closed at $1,169.60, and one investor narrative puts fair value near $1,477, citing retatrutide's Phase 3 results against pricing pressure.
She cites Chainalysis data showing $32M in crypto payments to gray-market peptide vendors in Q1 2026, up 159%, plus Chinese retatrutide imports.
Loading…